After abiraterone and enzalutamide established survival benefit in metastatic castration-resistant prostate cancer (mCRPC), a 2013 review by Leibowitz-Amit and Joshua posed the unresolved questions that still organize the field: whether an optimal order or combination of the available life-prolonging agents exists and can be identified prospectively; what mechanisms underlie primary and acquired resistance to second-generation hormonal therapy and whether they admit a unified explanation; and whether such resistance is irreversible or can reverse after treatment discontinuation, permitting rechallenge. Adjacent parts have been resolved — androgen receptor pathway inhibitors now move earlier into hormone-sensitive disease, first-line biomarker-selected combinations have phase 3 evidence, and the CARD trial anchored one sequencing decision — but the core remains open: no validated sequencing strategy or sequencing biomarker exists, resistance mechanisms are catalogued yet not unified into a clinically actionable account, and rechallenge rests only on small series. The problem asks for both the optimal deployment of androgen-directed therapy across the mCRPC disease course and the mechanistic explanation of its failure.

Background

Prostate cancer growth is driven by androgen receptor (AR) signaling, a nuclear hormone receptor transcriptional program activated by androgens such as testosterone. First-line treatment of metastatic disease is androgen deprivation therapy (ADT), which suppresses testosterone to castrate levels. Tumors that progress despite castrate testosterone are called castration-resistant prostate cancer (CRPC); when metastatic, mCRPC. Crucially, castration resistance rarely means androgen-independence: most CRPC remains dependent on AR signaling, which drives two "second-generation" hormonal therapies. Abiraterone acetate blocks CYP17A1, an enzyme required for androgen synthesis, and is given with prednisone; enzalutamide is a direct AR antagonist. Randomized trials in 2011-2014 showed both drugs prolong overall survival (OS, time from randomization to death from any cause) in mCRPC after docetaxel chemotherapy (COU-AA-301 and AFFIRM) and before chemotherapy (COU-AA-302 and PREVAIL), joining docetaxel, the next-generation taxane cabazitaxel, and the bone-seeking alpha-emitting radionuclide radium-223 as life-prolonging options. Efficacy is tracked by prostate-specific antigen (PSA, a secreted protein used as a biochemical disease marker; a confirmed 50% decline is a standard response criterion) and by radiographic progression-free survival (rPFS, time to objective radiographic progression or death). In this 2013 context, Leibowitz-Amit and Joshua's review in Current Opinion in Supportive and Palliative Care stated that the proper sequencing of the new drugs along the disease continuum remained an unresolved question, and that drug resistance — primary (present at first exposure) or acquired (emerging during treatment) — continued to be a major therapeutic obstacle; the review further raises the sub-questions of mechanism (CYP17 upregulation/intratumoral steroidogenesis, constitutively active AR splice variants such as AR-V7 — a truncated AR mRNA variant lacking the ligand-binding domain and therefore active without androgen — and stress-response pathways), possible reversibility of resistance after discontinuation allowing rechallenge, combination strategies, biomarkers to pick the best sequence for an individual patient, and integration of the new agents earlier in the disease course. The relevant mechanistic vocabulary for later work includes: intratumoral steroidogenesis (upregulated CYP17A1 and upstream steroid enzymes letting tumors make their own androgens; Mostaghel et al. 2011); glucocorticoid receptor (GR) bypass, in which the related nuclear receptor GR occupies AR-regulated genes and substitutes for AR signaling under antiandrogen pressure (Arora et al. 2013); lineage plasticity, the evolution of AR-indifferent or neuroendocrine phenotypes under sustained AR blockade (Beltran et al. 2016); and, on the therapeutic side, poly(ADP-ribose) polymerase (PARP) inhibitors, drugs effective in tumors with homologous recombination repair gene alterations such as BRCA1/2 loss (Robinson et al. 2015 mapped this genomic landscape).

Problem Statement

For men with metastatic castration-resistant prostate cancer, determine how the life-prolonging agents — abiraterone, enzalutamide, docetaxel, cabazitaxel, radium-223, and subsequently approved agents — should be deployed across the disease course to maximize clinical benefit (with the efficacy measure to be optimized — for example overall survival, radiographic progression-free survival, or PSA response), and explain why this therapy fails when it does. The single overarching objective joins three linked questions posed by the source review. (1) Sequencing and combination: does an optimal order or combination of these therapies exist, established by prospective rather than retrospective evidence, and can biomarkers identify the best sequence for the individual patient — including whether a second androgen receptor pathway inhibitor should follow the first (versus a switch of mechanism), and in what order and combination the agents should be used in the post-chemotherapy and pre-chemotherapy settings? (2) Resistance: what mechanisms account for primary and acquired resistance to second-generation hormonal therapy — the evidence-supported set, of which CYP17/steroidogenesis upregulation, constitutively active androgen-receptor splice variants, glucocorticoid-receptor bypass, and lineage plasticity are examples — and can these be integrated into a unified, clinically actionable explanation of escape from androgen-directed therapy — that is, a single account that links the proposed mechanisms to treatment decisions? (3) Reversibility: is such resistance irreversible, as classically assumed for chemotherapy, or can it sometimes reverse after treatment discontinuation so that rechallenge with the same agent is beneficial, and can reversibility be detected prospectively? The question concerns the clinical objective as a whole — improved, biomarker-guided deployment of androgen-directed therapy in mCRPC, the mechanistic explanation of its failure, and whether resistance can reverse after treatment discontinuation so that rechallenge is beneficial — not a proxy or a restricted sub-case; a single agent or resistance mechanism treated in isolation, without relation to the objective as a whole, lies outside that scope. No prospectively validated sequencing or combination strategy exists yet, so the sequencing and combination question is answered from the strongest available evidence, with prospective validation still the open step for any proposed strategy; the resistance and reversibility questions likewise rest on the available evidence and on what further evidence would confirm or refute the proposed account.

References

  1. Leibowitz-Amit R, Joshua AM. The changing landscape in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care 2013;7(3):243-248. DOI: 10.1097/SPC.0b013e328362ffef. https://doi.org/10.1097/SPC.0b013e328362ffef
  2. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005. DOI: 10.1056/NEJMoa1014618. https://doi.org/10.1056/NEJMoa1014618
  3. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-1197. DOI: 10.1056/NEJMoa1207506. https://doi.org/10.1056/NEJMoa1207506
  4. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-148. DOI: 10.1056/NEJMoa1209096. https://doi.org/10.1056/NEJMoa1209096
  5. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-433. DOI: 10.1056/NEJMoa1405095. https://doi.org/10.1056/NEJMoa1405095
  6. Loriot Y, Bianchini D, Ileana E, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24(7):1807-1812. DOI: 10.1093/annonc/mdt136. https://doi.org/10.1093/annonc/mdt136
  7. de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019;381:2506-2518. DOI: 10.1056/NEJMoa1911206. https://doi.org/10.1056/NEJMoa1911206
  8. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028-1038. DOI: 10.1056/NEJMoa1315815. https://doi.org/10.1056/NEJMoa1315815
  9. Armstrong AJ, Halabi S, Luo J, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J Clin Oncol 2019;37:1120-1129. DOI: 10.1200/JCO.18.01731. https://doi.org/10.1200/JCO.18.01731
  10. Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17:5913-5925. DOI: 10.1158/1078-0432.CCR-11-0728. https://doi.org/10.1158/1078-0432.CCR-11-0728
  11. Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013;155:1309-1322. DOI: 10.1016/j.cell.2013.11.012. https://doi.org/10.1016/j.cell.2013.11.012
  12. Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 2015;15:701-711. DOI: 10.1038/nrc4016. https://doi.org/10.1038/nrc4016
  13. Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 2016;22:298-305. DOI: 10.1038/nm.4045. https://doi.org/10.1038/nm.4045
  14. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215-1228. DOI: 10.1016/j.cell.2015.05.001. https://doi.org/10.1016/j.cell.2015.05.001
  15. Antonarakis ES, Zhang N, Saha J, et al. Prevalence and spectrum of AR ligand-binding domain mutations detected in circulating-tumor DNA across disease states in men with metastatic castration-resistant prostate cancer. JCO Precis Oncol 2024;8:e2300330. DOI: 10.1200/PO.23.00330. https://doi.org/10.1200/PO.23.00330
  16. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338-351. DOI: 10.1056/NEJMoa1702900. https://doi.org/10.1056/NEJMoa1702900
  17. Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386:1132-1142. DOI: 10.1056/NEJMoa2119115. https://doi.org/10.1056/NEJMoa2119115
  18. Chi KN, Rathkopf D, Smith MR, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer (MAGNITUDE). J Clin Oncol 2023;41:3339-3351. DOI: 10.1200/JCO.22.01649. https://doi.org/10.1200/JCO.22.01649
  19. Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 2023;402:291-303. DOI: 10.1016/S0140-6736(23)01055-3. https://doi.org/10.1016/S0140-6736(23)01055-3
  20. Francini E, Agarwal N, Castro E, et al. Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review. Eur Urol 2025;87:29-46. DOI: 10.1016/j.eururo.2024.09.008. https://doi.org/10.1016/j.eururo.2024.09.008
  21. Yamada Y, Beltran H. The treatment landscape of metastatic prostate cancer. Cancer Lett 2021;519:20-29. DOI: 10.1016/j.canlet.2021.06.010. https://doi.org/10.1016/j.canlet.2021.06.010
  22. Güner G, Arslan C. Evaluation of novel treatments for metastatic castration-resistant prostate cancer. Expert Opin Pharmacother 2026;27:273-289. DOI: 10.1080/14656566.2026.2652456. https://doi.org/10.1080/14656566.2026.2652456
  23. Nagaya N, Kanayama M, Nagata M, Horie S. Abiraterone rechallenge based on sequential testing of androgen receptor splice variant 7 expression in circulating tumor cells: a case report. Front Oncol 2020;10:495. DOI: 10.3389/fonc.2020.00495. https://doi.org/10.3389/fonc.2020.00495
  24. Gebrael G, Ostrowski M, Agarwal N. Metastatic prostate cancer: clinical trials to watch. Med 2025;6:100927. DOI: 10.1016/j.medj.2025.100927. https://doi.org/10.1016/j.medj.2025.100927